Brind.

Former Pfizer CSO Mikael Dolsten joins Maxion Therapeutics board

1 report, 1 independent Updated Oct 20
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Maxion Therapeutics announced the appointment of Mikael Dolsten as an independent Non-Executive Director to its Board. Dolsten, who previously served as Chief Scientific Officer at Pfizer, brings experience in translating scientific innovation into medicines. Maxion is a biotechnology company that develops antibody-based KnotBody® drugs.

From manilatimes.net

Why it matters

Some supportBrind's analysis of the reports

Dolsten will support Maxion in advancing its proprietary pipeline of KnotBody® therapeutics. Maxion's Chair noted that Dolsten has a proven ability to drive cutting-edge science through clinical evaluation and toward commercialization.

From manilatimes.net

Who's involved

  • Mikael DolstenAppointed independent Non-Executive Director to Maxion Therapeutics' Board
  • PfizerMikael Dolsten previously served as Chief Scientific Officer at Pfizer

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped